- Home
- TURN vs LPCN Comparison
TURN vs LPCN Comparison
Compare TURN & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TURN
- LPCN
- Stock Information
- Founded
- TURN 1981
- LPCN 1997
- Country
- TURN United States
- LPCN United States
- Employees
- TURN N/A
- LPCN N/A
- Industry
- TURN Finance/Investors Services
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- TURN Finance
- LPCN Health Care
- Exchange
- TURN Nasdaq
- LPCN Nasdaq
- Market Cap
- TURN 39.9M
- LPCN 16.1M
- IPO Year
- TURN N/A
- LPCN N/A
- Fundamental
- Price
- TURN N/A
- LPCN $3.10
- Analyst Decision
- TURN
- LPCN Strong Buy
- Analyst Count
- TURN 0
- LPCN 2
- Target Price
- TURN N/A
- LPCN $9.00
- AVG Volume (30 Days)
- TURN 17.2K
- LPCN 60.6K
- Earning Date
- TURN 01-01-0001
- LPCN 08-07-2025
- Dividend Yield
- TURN N/A
- LPCN N/A
- EPS Growth
- TURN N/A
- LPCN N/A
- EPS
- TURN N/A
- LPCN N/A
- Revenue
- TURN $194,813.00
- LPCN $3,674,834.00
- Revenue This Year
- TURN N/A
- LPCN N/A
- Revenue Next Year
- TURN N/A
- LPCN N/A
- P/E Ratio
- TURN N/A
- LPCN N/A
- Revenue Growth
- TURN 254.25
- LPCN N/A
- 52 Week Low
- TURN $3.12
- LPCN $2.68
- 52 Week High
- TURN $4.25
- LPCN $8.23
- Technical
- Relative Strength Index (RSI)
- TURN 55.65
- LPCN 43.66
- Support Level
- TURN $3.96
- LPCN $3.13
- Resistance Level
- TURN $4.03
- LPCN $3.23
- Average True Range (ATR)
- TURN 0.06
- LPCN 0.17
- MACD
- TURN 0.00
- LPCN -0.01
- Stochastic Oscillator
- TURN 83.33
- LPCN 15.69
About TURN 180 Degree Capital Corp.
180 Degree Capital Corp is active in the financial services domain. It is a non-diversified closed-end management investment company whose objective is to achieve long-term capital appreciation by making venture capital investments. It focuses its investments on companies commercializing and integrating products enabled by disruptive technologies mainly in the life sciences, precision medicine, and health industries.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.